What is the difference between Beijing Sinovac vaccine and Sinopharm vaccine? Which one is better, Beijing Sinovac vaccine or Sinopharm vaccine

Since the launch of COVID-19 vaccine, people have been full of doubts about the safety and effectiveness of COVID-19 vaccine. There are several kinds of COVID-19 vaccine in our country, and the choice of Xinguan vaccine is also quite difficult. Beijing Kexing and Sinopharm are both good.

1. Sinovac. Since the Phase III trial was conducted in several countries, the enrolled population was different, and the data were quite different, ranging from 9

1.25% in Türkiye to 50.65% in Brazil. But so far, no single dose data has been published in any country, and the data were all the trial data twice every 14 days.

2. National medicine. Beijing Biopharmaceutical has achieved a 7

protection rate of 2.5%, both based on data from two doses after vaccination. Currently, the formulation of China's national immunization strategy is also based on many factors, including vaccine capacity, anti epidemic pressure, strain, protection rate, etc. From the current situation in China, the vaccination strategy is relatively suitable. In fact, we don't need to deliberately choose a certain vaccine. Everyone should establish the concept of getting vaccinated as early as possible. As long as their physical conditions are met, they should get vaccinated as soon as possible to establish an immune barrier. World Health Expert Group: The vaccines provided by Sinopharm and Sinovac are safe and effective. The WHO Strategic Advisory Expert Group on Immunization said on March 31 that the relevant data of the two COVID-19 vaccines submitted by Sinopharm and Sinopharm showed that its protective effect met the requirements of WHO and would not cause harm to human beings. The WHO Immunization Strategy Advisory Expert Group held a press conference on the same day. Expert group chairman Alejandro Cravioto said at a press conference that the vaccine data submitted by the two Chinese companies clearly shows that the protective effect of these vaccines meets the requirements of the World Health Organization, which means that "the vaccine efficacy is around 50%, preferably close to 70%". The data submitted by the two companies also indicates that both vaccines are safe and non-toxic, and pose no harm to the human body. Kravioto said that the two COVID-19 vaccines, Sinopharm and Sinovac, first need to be approved by the World Health Organization or its recognized regulatory agencies. The WHO Strategic Advisory Expert Group on Immunization will provide recommendations for the use of these two vaccines, and hopes to publish the relevant recommendations before the end of April. At the beginning of this month, Margaret Harris, spokesperson for the World Health Organization, said that two vaccines from Sinopharm and Sinovac will soon receive emergency use permits from the World Health Organization. WHO has previously approved the provision of three types of COVID-19 vaccines, which are jointly developed by Pfizer Pharmaceuticals of the United States and German Biotech, AstraZeneca Pharmaceuticals of the United Kingdom and Oxford University, and Janssen Pharmaceuticals of Johnson&Johnson of the United States. The difference between Beijing Kexing and Sinopharm Biotech is that the COVID-19 vaccine produced by Beijing Kexing and Beijing Biotech is very good, and each has its own advantages. The vaccine of Beijing Biological Group has the same effect whether it is a new vaccine or a vaccine made in Beijing Science&Technology Co., Ltd., which has the effect of preventing COVID-19. Once again, it should be emphasized that both of these belong to inactivated virus vaccines, which have been approved by the national drug regulatory department and have good safety and immune effects. Both can be safely administered. (1) COVID-19 vaccine.

1. Vaccine effect. The WHO Immunization Strategy Advisory Group has completed its review of the vaccine. A large three phase multinational clinical trial showed that the effective rate of preventing symptomatic COVID-19 infection for more than 14 days was 79% and the preventive hospitalization rate was 79% when the interval between two doses of vaccine was 21 days. Due to the limited number of elderly individuals aged 60 and above participating in clinical trials, the effectiveness of this age group cannot be evaluated; However, the World Health Organization does not recommend setting an age limit for the vaccine, as preliminary data and auxiliary data on immunogenicity suggest that the vaccine may also have a protective effect on older adults.

2. Research and development institution: Beijing Institute of Biological Products Co., Ltd.

3. Vaccine name: inactivated COVID-19 vaccine (Vero cell)

6. Approval type: WHO emergency use. 2. Kexing Zhongwei COVID-19 Vaccine.

1. Vaccine effect. The WHO Immunization Strategy Advisory Group has completed its review of the vaccine. The research results on the vaccine effect show that this vaccine can prevent 51% of the vaccinators from developing disease symptoms, and can prevent severe COVID-19 disease and hospitalized treatment in 100% of the subjects. Given the small number of elderly people aged 60 and above participating in clinical trials, it is not possible to estimate the effectiveness of this age group; However, the World Health Organization does not recommend setting an age limit for the vaccine, as data collected during use in multiple countries and immunogenicity support data suggest that the vaccine may also have a protective effect on older adults. Research institution: Beijing Kexing Zhongwei Biotechnology Co., Ltd.

2. Name of vaccine: inactivated COVID-19 (Vero cell)

5. Approval type: WHO emergency use. Can Beijing Sinovac and Sinopharm be used together? It is best to use the same vaccine product for vaccination at this stage. If there are special circumstances where the vaccine cannot continue to be supplied and the recipient is vaccinated in a different location, and the same vaccine product cannot be vaccinated, the same manufacturer's vaccine product can be selected for vaccination. Both Sinovac and Beijing Biotech produce inactivated vaccines, so they can be mixed together. Three kinds of COVID-19 inactivated vaccine products that have been approved for marketing are respectively produced by Beijing Sinopharm Group China Biotechnology Co., Ltd. (Beijing Institute), Wuhan Biological Products Research Institute (Wuhan Institute), and Beijing Kexing Zhongwei Biological Technology Co., Ltd. (Kexing Zhongwei). This method amplifies the virus from Vero cells of African green monkeys, then inactivates the virus with β - lactone to retain the antigen component and induce an immune response in the body. Aluminum hydroxide is added to enhance immunogenicity. Do people who have already received two doses of inactivated vaccine need to be vaccinated again? Expert recommendation: For those who have received one dose of inactivated vaccine, it is recommended to complete the entire vaccination process with inactivated vaccine; For those who have already received two doses of inactivated vaccine, it is not recommended to strengthen with adenovirus vaccine at this time. Why is Beijing Sinovac vaccine cheaper than Sinopharm? The price of COVID-19 vaccine is 300 yuan per injection and 600 yuan for two injections, while that of COVID-19 vaccine is 200 yuan per injection and 400 yuan for two injections. For the issue of drug prices, Chinese pharmaceutical officials will determine prices based on their availability, safety, efficacy, and people's ability to pay. Beijing Kexing said that the price of COVID-19 vaccine is related to the order quantity, order time and dosage form. In addition, at present, the COVID-19 vaccine approved for emergency vaccination in China is inactivated vaccine, there is no alternative, and there is no evidence to prove which process vaccine is better. Given the current needs of epidemic prevention and control, any vaccine made for the purpose of disease prevention is acceptable for non contraindicated populations. Why doesn't Sinopharm use Sinopharm abroad? Because Sinopharm was the first to conduct research and clinical trials abroad, it has been widely used abroad. So far, at least 34 countries, including Indonesia, Türkiye, Brazil, Chile, Colombia, Uruguay, Laos, Mexico, Thailand and Malaysia, have all used it urgently. Countries all over the world have carried out COVID-19 vaccination work, and presidents and prime ministers of the following countries have been vaccinated with COVID-19 vaccine.

On the morning of January 13, President Joko of Indonesia inoculated China Sinovac with COVID-19 vaccine at the Presidential Palace in Jakarta.

On January 14, President Erdogan of Türkiye vaccinated China Sinovac with COVID-19 vaccine in a hospital in Ankara.

On March 9, Peruvian President Zagasti received the COVID-19 vaccine of China National Pharmaceutical Group in Lima, the capital.

On April 25, Senegalese President Saleh inoculated China National Pharmaceutical Group with COVID-19 vaccine at the presidential palace.

On May 26, President Ardell of Hungary vaccinated China National Pharmaceutical Group with COVID-19 vaccine in Budapest, the capital of Hungary. On June 28th, Hungarian Prime Minister Orban vaccinated China National Pharmaceutical Group.

On March 12, President Pinera of Chile received the COVID-19 Vaccination from Sinovac in a hospital in Santiago, the capital of Chile.

On August 15, Pakistani President Alwi inoculated China National Pharmaceutical Group with COVID-19 vaccine in Islamabad.

On September 18, Pakistani Prime Minister Imran Khan vaccinated China National Pharmaceutical Group with COVID-19 vaccine in Islamabad. In short, Beijing Biotech and Sinovac Biotech each have their own advantages, and their safety measures are both approved by the state. So, you don't have to deliberately wait for a vaccine from a certain brand, but rather choose which one to get vaccinated with.